
  
    
      
        Background_NNP
        With_IN the_DT publication_NN of_IN the_DT Antihypertensive_NNP and_CC
        Lipid-_NNP Lowering_NNP Treatment_NNP to_TO prevent_VB Heart_NNP Attack_NNP Trial_NNP
        (_( ALLHAT_NNP )_) ,_, the_DT role_NN of_IN peripheral_JJ alpha-_NN 1_CD antagonists_NNS in_IN the_DT
        treatment_NN of_IN hypertension_NN has_VBZ become_VBN controversial_JJ ._. The_DT
        doxazosin_NN arm_NN of_IN ALLHAT_NNP was_VBD stopped_VBN early_JJ ,_, due_JJ to_TO a_DT
        doubling_NN of_IN the_DT incidence_NN of_IN congestive_JJ heart_NN failure_NN in_IN
        this_DT group_NN ,_, as_IN compared_VBN to_TO the_DT low-dose_JJ chlorthalidone_NN arm_NN
        [_NN 1_CD ]_NN ._. Prior_RB to_TO this_DT publication_NN ,_, there_EX had_VBD been_VBN no_DT
        obvious_JJ suggestion_NN of_IN a_DT mechanism_NN by_IN which_WDT peripheral_JJ
        alpha-_NN 1_CD antagonists_NNS in_IN general_NN or_CC doxazosin_NN in_IN particular_NN
        would_MD be_VB inferior_JJ to_TO chlorthalidone_NN or_CC would_MD specifically_RB
        cause_VB CHF_NNP ._. Because_IN ALLHAT_NNP is_VBZ an_DT active-control_JJ trial_NN ,_, no_DT
        inferences_NNS can_MD be_VB made_VBN on_IN whether_IN this_DT increased_VBN incidence_NN
        of_IN CHF_NNP results_NNS from_IN a_DT harmful_JJ effect_NN of_IN doxazosin_NN ,_, a_DT
        beneficial_JJ effect_NN of_IN chlorthalidone_NN ,_, or_CC both_DT ._. Nonetheless_RB ,_,
        there_EX has_VBZ been_VBN a_DT large_JJ body_NN of_IN literature_NN dedicated_VBN to_TO the_DT
        positive_JJ effects_NNS of_IN peripheral_JJ alpha-_NN 1_CD antagonists_NNS on_IN
        surrogate_JJ endpoints_NNS such_JJ as_IN cholesterol_NN levels_NNS and_CC
        tolerability_NN ._. In_IN light_NN of_IN the_DT results_NNS of_IN ALLHAT_NNP ,_, we_PRP
        performed_VBD a_DT review_NN of_IN the_DT literature_NN on_IN doxazosin_NN ,_,
        terazosin_NN ,_, and_CC prazosin_NN ._.
      
      
        Methods_NNP
        Medline_NNP and_CC the_DT Cochrane_NNP databases_NNS were_VBD used_VBN to_TO identify_VB
        English-language_JJ papers_NNS on_IN peripheral_JJ alpha-_NN 1_CD antagonists_NNS
        in_IN studies_NNS targeting_VBG cardiovascular_JJ endpoints_NNS ,_, background_NN
        physiologic_JJ literature_NN ,_, or_CC any_DT studies_NNS suggesting_VBG
        mechanisms_NNS leading_VBG to_TO an_DT inferior_JJ performance_NN in_IN
        cardiovascular_JJ endpoints_NNS ._. Medline_NNP was_VBD searched_VBD from_IN 1966_CD to_TO
        the_DT present_NN with_IN the_DT key_JJ words_NNS "_'' doxazosin_NN ,_, "_'' "_'' prazosin_NN ,_, "_''
        "_'' terazosin_NN ,_, "_'' "_'' adrenergic_JJ alpha-antagonists_JJ ,_, "_'' or_CC "_'' alpha_NN
        blocker_NN ._. "_'' The_DT search_NN was_VBD then_RB limited_VBN to_TO clinical_JJ trials_NNS
        that_WDT had_VBD "_'' hypertension_NN "_'' as_IN a_DT key_JJ word_NN ._. Studies_NNS were_VBD
        included_VBN in_IN our_PRP$ review_NN if_IN they_PRP addressed_VBD either_CC one_CD or_CC a_DT
        combination_NN of_IN the_DT three_CD agents_NNS as_IN the_DT main_JJ focus_NN in_IN the_DT
        context_NN of_IN hypertension_NN therapy_NN and_CC if_IN they_PRP in_IN some_DT way_NN
        addressed_VBD the_DT outcomes_NNS of_IN interest_NN noted_VBD above_IN ._. Relevant_NNP
        data_NNS from_IN these_DT studies_NNS are_VBP reported_VBN descriptively_RB ._. Other_JJ
        relevant_JJ references_NNS were_VBD acquired_VBN from_IN bibliographic_JJ
        searches_NNS ._.
      
      
        Results_NNS
        
          Use_NN in_IN Hypertension_NNP and_CC Prostatism_NNP
          Evidence_NN suggests_VBZ that_DT alpha-_NN 1_CD antagonists_NNS are_VBP
          frequently_RB prescribed_VBN for_IN hypertension_NN ,_, but_CC there_EX are_VBP few_JJ
          published_VBN data_NNS concerning_VBG the_DT prevalence_NN of_IN the_DT routine_JJ
          use_NN of_IN peripheral_JJ alpha-_NN 1_CD antagonists_NNS ,_, the_DT prevalence_NN
          according_VBG to_TO co-morbid_JJ conditions_NNS such_JJ as_IN benign_JJ
          prostatic_JJ hypertrophy_NN and_CC the_DT usual_JJ duration_NN of_IN therapy_NN ._.
          In_IN the_DT sixth_JJ report_NN of_IN the_DT Joint_NNP National_NNP Committee_NNP on_IN
          Prevention_NNP ,_, Detection_NNP ,_, Evaluation_NNP ,_, and_CC Treatment_NNP of_IN High_NNP
          Blood_NNP Pressure_NN (_( JNC_NNP VI_NNP )_) ,_, peripheral_JJ alpha-_NN 1_CD antagonists_NNS
          are_VBP recommended_VBN not_RB only_RB as_IN second-line_JJ anti-hypertensive_JJ
          therapy_NN after_IN low-dose_JJ diuretics_NNS and_CC beta_NN blockers_NNS ,_, but_CC
          also_RB for_IN specific_JJ indications_NNS such_JJ as_IN therapy_NN in_IN men_NNS with_IN
          hypertension_NN and_CC prostatism_NN [_NN 2_CD ]_NN ._. Alpha-_NNP 1_CD antagonists_NNS
          represent_VBP effective_JJ therapy_NN for_IN prostatism_NN ,_, and_CC fifty_NN
          percent_NN of_IN men_NNS have_VBP histologic_JJ evidence_NN of_IN BPH_NNP by_IN 60_CD
          years_NNS of_IN age_NN [_NN 3_CD 4_CD ]_NN ._. The_DT National_NNP Ambulatory_NNP Medical_NNP
          Care_NNP Survey_NN reported_VBD that_IN the_DT number_NN of_IN people_NNS on_IN any_DT
          type_NN of_IN peripheral_JJ alpha-_NN 1_CD antagonist_NN in_IN 1995_CD was_VBD
          approximately_RB 6_CD to_TO 7_CD %_NN of_IN those_DT with_IN hypertension_NN [_NN 5_CD ]_NN ._.
          About_IN 80_CD %_NN of_IN surveyed_VBN physicians_NNS would_MD choose_VB these_DT drugs_NNS
          as_IN a_DT first-line_JJ blood_NN pressure_NN agent_NN for_IN patients_NNS with_IN
          hypertension_NN and_CC symptoms_NNS of_IN BPH_NNP [_NN 6_CD ]_NN ._.
        
        
          Weight_NNP and_CC Fluid_NNP Status_NNP
          Peripheral_NNP alpha-_NN 1_CD antagonists_NNS were_VBD consistently_RB
          associated_VBN with_IN fluid_JJ retention_NN ._. A_DT 1984_CD study_NN of_IN prazosin_NN
          reported_VBN by_IN Bauer_NNP revealed_VBD increases_NNS in_IN plasma_NN volume_NN ,_,
          interstitial_NN fluid_JJ volume_NN ,_, and_CC extracellular_NN fluid_JJ volume_NN
          following_VBG both_DT short-term_JJ and_CC long-term_JJ therapy_NN [_NN 7_CD ]_NN ._.
          In_IN this_DT study_NN of_IN 14_CD hypertensive_JJ men_NNS ,_, there_EX was_VBD a_DT
          significant_JJ 1_CD ._. 4_CD L_NNP average_JJ increase_NN in_IN ECFV_NNP ,_, with_IN a_DT 200_CD mL_NN
          average_JJ increase_NN in_IN plasma_NN volume_NN (_( measured_VBN with_IN
          radioisotopic_JJ assays_NNS )_) that_WDT occurred_VBD within_IN 3_CD -_: 6_CD weeks_NNS of_IN
          initiation_NN ,_, lasted_VBD during_IN 5_CD to_TO 6_CD months_NNS of_IN chronic_JJ
          therapy_NN ,_, and_CC was_VBD still_RB present_JJ during_IN a_DT two-week_JJ washout_NN
          period_NN ._. There_EX was_VBD no_DT weight_NN change_NN in_IN that_DT study_NN ,_, but_CC two_CD
          other_JJ studies_NNS demonstrated_VBD both_DT an_DT increase_NN in_IN weight_NN as_RB
          well_RB as_IN laboratory_NN changes_NNS consistent_JJ with_IN volume_NN
          expansion_NN for_IN prazosin_NN [_NN 8_CD 9_CD ]_NN ._. Bauer_NNP and_CC his_PRP$ colleagues_NNS
          suggested_VBD that_IN a_DT net_JJ increase_NN in_IN total_JJ body_NN sodium_NN from_IN
          an_DT acute_JJ renal_JJ effect_NN of_IN prazosin_NN was_VBD offset_VBN by_IN a_DT
          decrease_NN in_IN actual_JJ body_NN weight_NN ._. They_PRP also_RB demonstrated_VBD
          that_IN the_DT fractional_JJ excretion_NN of_IN sodium_NN was_VBD unchanged_JJ
          during_IN treatment_NN ,_, and_CC further_RBR suggested_VBD that_IN the_DT acute_JJ
          changes_NNS were_VBD followed_VBN by_IN chronic_JJ sodium_NN homeostasis_NNS and_CC
          maintenance_NN of_IN the_DT increased_VBN total_JJ body_NN sodium_NN ._.
          The_DT VA_NNP Cooperative_NNP Study_NNP on_IN Antihypertensive_NNP agents_NNS
          was_VBD a_DT double-blind_JJ ,_, randomized_JJ controlled_VBN trial_NN comparing_VBG
          atenolol_NN ,_, captopril_NN ,_, clonidine_NN ,_, diltiazem_NN ,_,
          hydrochlorothiazide_NN ,_, prazosin_NN ,_, and_CC placebo_NN for_IN
          differences_NNS in_IN antihypertensive_JJ efficacy_NN in_IN 1_CD ,_, 105_CD men_NNS who_WP
          had_VBD mild_JJ diastolic_JJ hypertension_NN [_NN 10_CD ]_NN ._. A_DT highly_RB
          significant_JJ weight_NN gain_NN of_IN 1_CD kilogram_NN was_VBD observed_VBN at_IN 8_CD
          weeks_NNS with_IN prazosin_NN compared_VBN to_TO baseline_NN (_( p_NN <_NN ._. 001_CD )_) ,_,
          and_CC this_DT gain_NN was_VBD also_RB statistically_RB significant_JJ when_WRB
          compared_VBN to_TO the_DT 8_CD -_: week_NN weight_NN changes_NNS in_IN all_DT other_JJ groups_NNS
          that_WDT had_VBD experienced_VBN either_CC weight_NN loss_NN or_CC no_DT mean_JJ weight_NN
          change_NN (_( p_NN <_NN 0_CD ._. 05_CD )_) ._. The_DT prazosin_NN arm_NN had_VBD the_DT highest_JJS
          rate_NN of_IN adverse_JJ effects_NNS ,_, leading_VBG to_TO discontinuation_NN of_IN
          treatment_NN ._. The_DT termination_NN rate_NN of_IN 13_CD ._. 8_CD %_NN was_VBD higher_JJR than_IN
          the_DT termination_NN rate_NN from_IN adverse_JJ effects_NNS for_IN clonidine_NN
          (_( 10_CD ._. 1_LS %_NN )_) ,_, and_CC significantly_RB higher_JJR than_IN the_DT rates_NNS for_IN
          captopril_NN (_( 4_CD ._. 8_CD %_NN )_) ,_, atenolol_NN (_( 2_CD ._. 2_LS %_NN )_) ,_, or_CC hydrochlorothiazide_NN
          (_( 1_CD ._. 1_LS %_NN )_) [_NN 11_CD ]_NN ._. The_DT number_NN of_IN men_NNS treated_VBN with_IN prazosin_NN
          decreased_VBD from_IN 62_CD at_IN the_DT beginning_NN of_IN the_DT trial_NN to_TO 28_CD by_IN
          the_DT end_NN ._. The_DT average_JJ weight_NN gain_NN of_IN 0_CD ._. 5_CD kilograms_NNS from_IN
          baseline_NN was_VBD no_RB longer_RB statistically_RB significant_JJ at_IN one_CD
          year_NN of_IN therapy_NN when_WRB compared_VBN to_TO the_DT original_JJ baseline_NN
          weight_NN or_CC the_DT other_JJ therapies_NNS ._.
          Safety_NNP and_CC tolerability_NN trials_NNS with_IN terazosin_NN have_VBP
          shown_VBN similar_JJ results_NNS (_( Table_NNP 1_LS )_) ._. Patients_NNS treated_VBD with_IN
          terazosin_NN tended_VBD to_TO gain_VB about_IN 1_CD kilogram_NN from_IN baseline_NN
          on_IN active_JJ therapy_NN during_IN these_DT trials_NNS ,_, and_CC those_DT on_IN
          placebo_NN therapy_NN lost_VBD weight_NN ._. Two_CD of_IN the_DT randomized_JJ trials_NNS
          included_VBD a_DT phase_NN for_IN withdrawal_NN from_IN active_JJ therapy_NN ,_, with_IN
          weight_NN information_NN reported_VBN by_IN Ruoff_NNP [_NN 12_CD ]_NN ._. Withdrawal_NNP
          from_IN active_JJ therapy_NN was_VBD associated_VBN with_IN a_DT loss_NN of_IN 1_CD ._. 3_CD
          kilograms_NNS ._.
          Doxazosin_NNP has_VBZ also_RB been_VBN associated_VBN with_IN volume_NN
          expansion_NN ._. A_DT physiology_NN study_NN reported_VBN by_IN Lund-_NNP Johansen_NNP
          demonstrated_VBD a_DT plasma_NN volume_NN fluid_JJ expansion_NN of_IN about_IN 10_CD %_NN
          when_WRB compared_VBN to_TO baseline_NN values_NNS [_NN 13_CD ]_NN ._. Larger_NNP
          randomized_JJ controlled_VBD trials_NNS have_VBP also_RB consistently_RB
          demonstrated_VBN that_IN patients_NNS treated_VBN with_IN doxazosin_NN gain_NN
          weight_NN ,_, as_IN summarized_VBD in_IN Table_NNP 2_CD ._. While_IN patients_NNS treated_VBN
          with_IN doxazosin_NN tend_VBP to_TO gain_VB weight_NN ,_, patients_NNS on_IN placebo_NN
          therapy_NN lost_VBD weight_NN ._. The_DT Treatment_NNP of_IN Mild_NNP Hypertension_NNP
          Study_NNP (_( TOMHS_NNP )_) trial_NN is_VBZ a_DT notable_JJ exception_NN for_IN the_DT trend_NN
          towards_IN weight_NN gain_NN [_NN 14_CD ]_NN ._. All_DT five_CD treatment_NN groups_NNS
          and_CC the_DT placebo_NN group_NN received_VBD intensive_JJ dietary_JJ
          counseling_NN aimed_VBN at_IN weight_NN loss_NN ,_, and_CC all_DT groups_NNS lost_VBD
          weight_NN without_IN significant_JJ differences_NNS between_IN trial_NN
          arms_NNS ._.
        
        
          Neurohormonal_NNP and_CC Cellular_NNP Effects_NNPS
          Physiologic_NNP studies_NNS with_IN small_JJ numbers_NNS of_IN participants_NNS
          are_VBP by_IN nature_NN underpowered_JJ to_TO detect_VB meaningful_JJ
          population_NN differences_NNS ,_, but_CC may_MD provide_VB a_DT starting_NN point_NN
          when_WRB such_JJ data_NNS are_VBP not_RB available_JJ ._. Peripheral_NNP alpha-_NN 1_CD
          antagonists_NNS were_VBD associated_VBN with_IN perturbations_NNS in_IN
          neurohormonal_NN levels_NNS in_IN various_JJ studies_NNS ._. In_IN particular_JJ ,_,
          peripheral_JJ alpha-_NN 1_CD antagonists_NNS are_VBP associated_VBN with_IN an_DT
          increase_NN in_IN plasma_NN norepinephrine_NN in_IN diverse_JJ patient_NN
          populations_NNS ,_, as_IN summarized_VBD in_IN Table_NNP 3_CD ._. This_DT table_NN
          reflects_VBZ increases_NNS in_IN norepinephrine_NN in_IN normotensive_JJ
          patients_NNS ,_, hypertensive_JJ patients_NNS ,_, and_CC patients_NNS with_IN
          chronic_JJ congestive_JJ heart_NN failure_NN from_IN a_DT variety_NN of_IN these_DT
          small_JJ studies_NNS ._.
          Several_JJ lines_NNS of_IN evidence_NN suggest_VBP that_WDT elevated_JJ
          catecholamine_NN levels_NNS are_VBP cardiotoxic_JJ [_NN 15_CD ]_NN ._. Elevated_NNP
          plasma_NN norepinephrine_NN levels_NNS are_VBP hypothesized_VBN to_TO cause_VB
          direct_JJ myocardial_NN damage_NN through_IN many_JJ mechanisms_NNS ,_, which_WDT
          may_MD be_VB amplified_VBN by_IN concomitant_NN alpha-_NN 1_CD blockade_NN ._. In_IN
          rats_NNS ,_, norepinephrine_NN stimulates_NNS apoptosis_NNS ,_, which_WDT is_VBZ
          mediated_JJ through_IN beta_NN receptors_NNS [_NN 16_CD ]_NN ._. In_IN addition_NN ,_,
          alpha-_NN 1_CD cardiac_JJ receptors_NNS inhibit_VBP this_DT response_NN in_IN rat_NN
          myocytes_NNS [_NN 17_CD ]_NN ._. The_DT increased_VBN concentration_NN of_IN
          norepinephrine_NN leading_VBG to_TO cardiac_JJ beta_NN receptor_NN
          stimulation_NN combined_VBN with_IN alpha-_NN 1_CD receptor_NN inhibition_NN may_MD
          lead_VB to_TO increased_VBN apoptosis_NNS in_IN myocytes_NNS ._.
          Other_JJ hormones_NNS that_WDT are_VBP associated_VBN with_IN cardiovascular_JJ
          disease_NN are_VBP affected_VBN by_IN peripheral_JJ alpha-_NN 1_CD antagonists_NNS ._.
          Endothelin-_NNP 1_CD is_VBZ a_DT vascular_NN hormone_NN ,_, which_WDT may_MD play_VB a_DT role_NN
          in_IN the_DT generation_NN and_CC maintenance_NN of_IN heart_NN failure_NN [_NN 18_CD ]_NN
          ._. In_IN hypertensive_JJ patients_NNS ,_, doxazosin_NN lowers_VBZ von_NNP
          Willebrand_NNP factor_NN commensurate_JJ with_IN blood_NN pressure_NN ,_, but_CC
          it_PRP does_VBZ not_RB lower_JJR high_JJ levels_NNS of_IN endothelin-_NN 1_CD while_IN
          atenolol_NN does_VBZ [_NN 19_CD ]_NN ._.
          Other_JJ mechanisms_NNS for_IN cellular_JJ injury_NN have_VBP been_VBN
          suggested_VBN ._. Hooper_NNP proposed_VBD that_IN peripheral_JJ alpha-_NN 1_CD
          antagonists_NNS alter_VBP cellular_JJ repair_NN mechanisms_NNS ,_, possibly_RB
          causing_VBG cardiac_JJ damage_NN ._. He_PRP noted_VBD that_IN prazosin_NN blocks_NNS
          heat_NN shock_NN protein_NN expression_NN in_IN myocardium_NN ,_, and_CC it_PRP has_VBZ
          been_VBN hypothesized_VBN that_IN this_DT may_MD leave_VB myocardium_NN more_RBR
          vulnerable_JJ to_TO injury_NN [_NN 20_CD ]_NN ._.
        
        
          Epidemiological_NNP and_CC Clinical_NNP Trial_NNP Data_NNP
          Between_IN 1966_CD and_CC 2001_CD ,_, there_EX were_VBD 188_CD published_VBN
          cardiovascular_JJ randomized_JJ controlled_VBN trials_NNS related_VBN to_TO
          the_DT treatment_NN of_IN hypertension_NN with_IN the_DT use_NN of_IN peripheral_JJ
          alpha-_NN 1_CD antagonists_NNS ._. Among_IN these_DT ,_, only_RB ALLHAT_NNP
          specifically_RB assessed_VBD differences_NNS in_IN cardiovascular_JJ
          endpoints_NNS resulting_VBG from_IN control_NN of_IN hypertension_NN with_IN a_DT
          peripheral_JJ alpha-_NN 1_CD antagonist_NN ._. Most_JJS of_IN these_DT trials_NNS
          focused_VBN on_IN surrogate_JJ endpoints_NNS such_JJ as_IN equivalence_NN of_IN
          blood-pressure_JJ reduction_NN and_CC effects_NNS on_IN cholesterol_NN ._.
          Other_JJ studies_NNS focused_VBN on_IN tolerability_NN and_CC pharmacology_NN ._.
          There_EX are_VBP no_DT case_NN control_NN ,_, cohort_NN ,_, or_CC other_JJ studies_NNS that_WDT
          analyzed_VBD the_DT impact_NN of_IN these_DT agents_NNS on_IN cardiovascular_JJ
          endpoints_NNS ._. Using_VBG data_NNS from_IN other_JJ trials_NNS may_MD offer_VB a_DT
          partial_JJ framework_NN for_IN the_DT interpretation_NN of_IN newer_JJR
          findings_NNS ._.
          ALLHAT_NNP demonstrated_VBD a_DT highly_RB statistically_RB
          significant_JJ ,_, near_IN doubling_VBG in_IN the_DT incidence_NN of_IN heart_NN
          failure_NN in_IN the_DT doxazosin_NN arm_NN compared_VBN to_TO heart_NN failure_NN
          occurrences_NNS in_IN the_DT chlorthalidone_NN arm_NN ._. Although_IN there_EX was_VBD
          no_DT difference_NN in_IN the_DT primary_JJ outcome_NN of_IN CHD_NNP or_CC the_DT
          secondary_JJ outcome_NN of_IN total_JJ mortality_NN ,_, there_EX were_VBD small_JJ
          but_CC statistically_RB significant_JJ increases_NNS in_IN the_DT secondary_JJ
          outcomes_NNS of_IN angina_NN (_( RR_NNP 1_CD ._. 16_CD ,_, 95_CD %_NN CI_NNP 1_CD ._. 05_CD -_: 1_CD ._. 27_CD )_) and_CC stroke_NN
          (_( RR_NNP 1_CD ._. 19_CD ,_, 95_CD %_NN CI_NNP 1_CD ._. 01_CD -_: 1_CD ._. 40_CD )_) ._. Since_IN ALLHAT_NNP is_VBZ a_DT
          comparative_JJ trial_NN ,_, we_PRP know_VBP that_DT doxazosin_NN is_VBZ associated_VBN
          with_IN more_RBR adverse_JJ cardiovascular_JJ outcomes_NNS than_IN low-dose_JJ
          chlorthalidone_NN ,_, but_CC we_PRP do_VBP not_RB know_VB how_WRB doxazosin_NN might_MD
          compare_VB with_IN placebo_NN ._. The_DT SHEP_NNP trial_NN ,_, however_RB ,_, does_VBZ
          provide_VB a_DT comparison_NN between_IN chlorthalidone_NN and_CC placebo_NN
          therapy_NN for_IN a_DT reference_NN point_NN of_IN heart_NN failure_NN ,_, although_IN
          the_DT study_NN populations_NNS have_VBP different_JJ demographic_JJ and_CC
          blood_NN pressure_NN distributions_NNS [_NN 21_CD ]_NN ._. The_DT SHEP_NNP trial_NN
          included_VBD 4_CD ,_, 736_CD people_NNS aged_VBN 60_CD and_CC older_JJR who_WP had_VBD a_DT
          systolic_JJ blood_NN pressure_NN of_IN 160_CD to_TO 219_CD mmHg_NN and_CC a_DT
          diastolic_JJ blood_NN pressure_NN of_IN less_JJR than_IN 90_CD mmHg_NN ._. Subjects_NNP
          were_VBD randomized_JJ to_TO low-dose_JJ diuretics_NNS or_CC placebo_NN ,_, and_CC
          were_VBD followed_VBN for_IN an_DT average_NN of_IN 4_CD ._. 5_CD years_NNS for_IN major_JJ CV_NNP
          events_NNS ._. Comparisons_NNP between_IN those_DT randomized_JJ to_TO active_JJ
          therapy_NN and_CC those_DT on_IN placebo_NN demonstrated_VBN nearly_RB a_DT 50_CD %_NN
          reduction_NN in_IN fatal_JJ and_CC nonfatal_NN heart_NN failure_NN events_NNS (_( RR_NNP
          0_CD ._. 51_CD ,_, 95_CD %_NN CI_NNP 0_CD ._. 37_CD -_: 0_CD ._. 71_CD )_) ._. The_DT rates_NNS of_IN CHF_NNP in_IN SHEP_NNP
          participants_NNS treated_VBN with_IN diuretics_NNS and_CC placebo_NN were_VBD 5_CD
          and_CC 10_CD per_IN 1_CD ,_, 000_CD person-years_JJ ,_, respectively_RB ._. In_IN
          comparison_NN ,_, the_DT rates_NNS of_IN CHF_NNP in_IN ALLHAT_NNP participants_NNS
          treated_VBN with_IN diuretics_NNS and_CC doxazosin_NN were_VBD 10_CD and_CC 20_CD per_IN
          1_CD ,_, 000_CD person-years_JJ ,_, respectively_RB ._. If_IN low-dose_JJ
          chlorthalidone_NN has_VBZ a_DT similar_JJ risk_NN reduction_NN in_IN the_DT ALLHAT_NNP
          population_NN ,_, and_CC halves_VBZ the_DT incidence_NN of_IN clinical_JJ heart_NN
          failure_NN events_NNS compared_VBN to_TO no_DT therapy_NN ,_, the_DT effect_NN of_IN
          doxazosin_NN would_MD be_VB comparable_JJ to_TO that_DT of_IN the_DT placebo_NN arm_NN
          in_IN the_DT SHEP_NNP trial_NN ._.
        
      
      
        Conclusions_NNP
        The_DT report_NN of_IN the_DT doxazosin_NN arm_NN termination_NN in_IN ALLHAT_NNP
        was_VBD published_VBN in_IN April_NNP ,_, 2000_CD ._. At_IN that_DT time_NN ,_, the_DT results_NNS of_IN
        the_DT ALLHAT_NNP trial_NN were_VBD unexpected_JJ ,_, given_VBN the_DT potential_JJ
        association_NN between_IN high_JJ dose_NN diuretics_NNS and_CC the_DT risk_NN of_IN
        sudden_JJ death_NN [_NN 22_CD ]_NN ,_, and_CC the_DT favorable_JJ effect_NN of_IN
        peripheral_JJ alpha-_NN 1_CD antagonists_NNS on_IN lipid_NN profiles_NNS [_NN 14_CD ]_NN ._.
        Comparing_VBG data_NNS from_IN other_JJ studies_NNS suggests_VBZ the_DT possibility_NN
        that_IN the_DT beneficial_JJ effects_NNS of_IN peripheral_JJ alpha-_NN 1_CD
        antagonists_NNS for_IN lowering_VBG blood_NN pressure_NN may_MD be_VB nullified_VBN by_IN
        a_DT negative_JJ effect_NN ,_, or_CC that_IN other_JJ antihypertensives_NNS have_VBP
        positive_JJ actions_NNS beyond_IN their_PRP$ antihypertensive_JJ effects_NNS ._.
        Those_DT treated_VBN with_IN doxazosin_NN in_IN ALLHAT_NNP had_VBD a_DT mean_JJ blood_NN
        pressure_NN that_WDT was_VBD 2_CD to_TO 3_CD mmHg_NN higher_JJR than_IN the_DT mean_JJ blood_NN
        pressure_NN of_IN those_DT treated_VBN with_IN chlorthalidone_NN ._. Based_VBN on_IN
        Framingham_NNP Heart_NNP Study_NNP logistic_JJ regression_NN coefficients_NNS ,_,
        this_DT 2_CD to_TO 3_CD mmHg_NN difference_NN in_IN systolic_JJ blood_NN pressure_NN is_VBZ
        associated_VBN with_IN an_DT increased_VBN relative_JJ risk_NN of_IN only_RB 1_CD ._. 06_CD to_TO
        1_CD ._. 09_CD [_NN 23_CD ]_NN ._. From_IN available_JJ data_NNS ,_, it_PRP appears_VBZ that_IN this_DT
        average_JJ difference_NN in_IN systolic_JJ blood_NN pressure_NN is_VBZ not_RB large_JJ
        enough_RB to_TO double_VB the_DT average_JJ incidence_NN of_IN CHF_NNP ._.
        The_DT literature_NN suggests_VBZ several_JJ mechanisms_NNS by_IN which_WDT
        peripheral_JJ alpha-_NN 1_CD antagonists_NNS in_IN general_NN and_CC doxazosin_NN in_IN
        particular_NN might_MD prove_VB inferior_JJ to_TO other_JJ types_NNS of_IN
        antihypertensive_JJ therapy_NN ._. They_PRP are_VBP associated_VBN with_IN a_DT mild_JJ
        volume_NN expansion_NN ,_, which_WDT may_MD precipitate_NN the_DT clinical_JJ
        presentation_NN of_IN heart_NN failure_NN in_IN those_DT with_IN subclinical_JJ
        disease_NN ._. If_IN this_DT is_VBZ the_DT mechanism_NN responsible_JJ for_IN
        increasing_VBG the_DT incidence_NN of_IN CHF_NNP in_IN the_DT ALLHAT_NNP trial_NN ,_, it_PRP
        would_MD be_VB consistent_JJ with_IN the_DT early_JJ divergence_NN of_IN the_DT
        Kaplan-_NNP Meier_NNP curves_NNS in_IN that_DT study_NN ._.
        Peripheral_NNP alpha-_NN 1_CD antagonists_NNS also_RB cause_VBP neurohormonal_NN
        changes_NNS during_IN chronic_JJ therapy_NN ._. The_DT long-term_JJ ramifications_NNS
        of_IN these_DT changes_NNS for_IN patients_NNS being_VBG treated_VBN for_IN
        hypertension_NN are_VBP not_RB known_VBN ._. These_DT drugs_NNS appear_VBP to_TO cause_VB
        increases_NNS in_IN norepinephrine_NN ,_, and_CC this_DT increase_NN may_MD nullify_VB
        the_DT beneficial_JJ effect_NN of_IN lowered_VBD blood_NN pressure_NN on_IN the_DT
        occurrence_NN of_IN CHF_NNP ._. Not_RB only_RB are_VBP increased_VBN plasma_NN
        catecholamines_NNS a_DT central_JJ feature_NN in_IN heart_NN failure_NN ,_, they_PRP are_VBP
        now_RB a_DT recommended_VBN target_NN for_IN effective_JJ life-prolonging_JJ
        therapy_NN [_NN 24_CD 25_CD 26_CD ]_NN ._.
        Given_VBN that_DT doxazosin_NN is_VBZ not_RB as_RB effective_JJ as_IN
        chlorthalidone_NN in_IN reducing_VBG the_DT cardiovascular_JJ complications_NNS
        of_IN hypertension_NN ,_, several_JJ questions_NNS remain_VBP ._. There_EX is_VBZ still_RB a_DT
        paucity_NN of_IN information_NN regarding_VBG the_DT absolute_JJ risk_NN
        reduction_NN for_IN clinical_JJ heart_NN failure_NN or_CC other_JJ
        cardiovascular_JJ events_NNS afforded_VBN by_IN peripheral_JJ alpha-_NN 1_CD
        antagonists_NNS in_IN a_DT variety_NN of_IN populations_NNS ._. Differentiation_NNP of_IN
        the_DT mechanism_NN for_IN reduced_VBN protection_NN compared_VBN to_TO diuretics_NNS
        would_MD be_VB interesting_JJ but_CC difficult_JJ to_TO accomplish_VB ._. For_IN heart_NN
        failure_NN in_IN particular_JJ ,_, the_DT increase_NN in_IN symptomatic_JJ episodes_NNS
        of_IN CHF_NNP may_MD be_VB due_JJ to_TO hemodynamic_JJ effects_NNS of_IN doxazosin_NN
        unmasking_VBG incipient_NN heart_NN failure_NN ,_, direct_JJ myocardial_NN
        injury_NN ,_, or_CC both_DT ._. Chronic_NNP volume_NN loading_NN may_MD not_RB only_RB unmask_VB
        subclinical_JJ ventricular_NN dysfunction_NN ,_, but_CC may_MD possibly_RB
        contribute_VB to_TO worsening_VBG ventricular_NN function_NN over_IN time_NN ._.
        Whatever_WDT mechanisms_NNS were_VBD responsible_JJ for_IN the_DT heart_NN
        failure_NN findings_NNS in_IN ALLHAT_NNP ,_, the_DT results_NNS support_VBP the_DT current_JJ
        national_JJ recommendations_NNS to_TO use_VB low-dose_JJ diuretics_NNS or_CC
        beta-blockers_JJ as_IN first_JJ line_NN agents_NNS for_IN the_DT pharmacologic_JJ
        treatment_NN of_IN uncomplicated_JJ hypertension_NN ._.
      
      
        Competing_VBG Interests_NNP
        Dr_NNP ._. Psaty_NNP was_VBD a_DT Merck_NNP /_NN SER_NNP Clinical_NNP Epidemiology_NNP Fellow_NNP
        (_( co-sponsored_VBN by_IN the_DT Merck_NNP Co_NNP ._. Foundation_NNP ,_, Rahway_NNP ,_, NJ_NNP ,_, and_CC
        the_DT Society_NNP for_IN Epidemiologic_NNP Research_NNP ,_, Baltimore_NNP ,_, MD_NNP )_) ,_, and_CC
        a_DT member_NN of_IN the_DT Events_NNS Committee_NNP of_IN the_DT HERS_NNP trial_NN funded_VBN
        by_IN Wyeth_NNP Ay_NNP erst_NN ._.
      
    
  
